Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Galecto (GLTO)
NASDAQ:GLTO
Holding GLTO?
Track your performance easily
GLTO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.50 - $23.50
Previous Close$6.86
Volume39.51K
Average Volume (3M)37.86K
Market Cap
$8.86M
Enterprise Value-$10.81M
Total Cash (Recent Filing)$19.68M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Apr 25, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.33
Shares Outstanding1,316,989
10 Day Avg. Volume19,816
30 Day Avg. Volume37,858
Standard Deviation0.26
R-Squared0.05
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.43
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.50
Forecast
1Y Price Target
$10.00Price Target Upside43.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Galecto News
PremiumCompany Announcements
Galecto, Inc. Announces Strategic Shift and Financial Overview
PremiumCompany Announcements
Galecto Appoints Dr. Amy Wechsler to Board
Ownership Overview
7.40%
Insiders
16.91% Mutual Funds
7.59% Other Institutional Investors
67.46% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GLTO FAQ
What was Galecto’s price range in the past 12 months?
Galecto lowest stock price was $6.50 and its highest was $23.50 in the past 12 months.
What is Galecto’s market cap?
Currently, no data Available
When is Galecto’s upcoming earnings report date?
Galecto’s upcoming earnings report date is Apr 25, 2025 which is in 169 days.
How were Galecto’s earnings last quarter?
Galecto released its earnings results on Nov 01, 2024. The company reported -$3.39 earnings per share for the quarter, beating the consensus estimate of -$3.7 by $0.31.
Is Galecto overvalued?
According to Wall Street analysts Galecto’s price is currently Undervalued.
Does Galecto pay dividends?
Galecto does not currently pay dividends.
What is Galecto’s EPS estimate?
Galecto’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galecto have?
Galecto has 1,316,989 shares outstanding.
What happened to Galecto’s price movement after its last earnings report?
Galecto reported an EPS of -$3.39 in its last earnings report, beating expectations of -$3.7. Following the earnings report the stock price went down -1.46%.
Which hedge fund is a major shareholder of Galecto?
Currently, no hedge funds are holding shares in GLTO
---
Galecto Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (43.06% Upside)
$10.00 (43.06% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.0%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.93%
12-Months-Change
Fundamentals
Return on Equity
-72.61%
Trailing 12-Months
Asset Growth
-53.29%
Trailing 12-Months
Company Description
Galecto
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis & impact a broad range of fibrotic & related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
---
GLTO Stock 12 Month Forecast
Average Price Target
$10.00
▲(43.06% Upside)
Technical Analysis
Ovid Therapeutics
―
Aurinia Pharmaceuticals
―
Fate Therapeutics
―
Bioxcel Therapeutics
―
Best Analysts Covering GLTO
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-40.78%
reiterated a buy rating 21 days ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -40.78% per trade.
---